Clobazam and Metabolite, Quantitative, Serum or Plasma
Use to optimize drug therapy and monitor patient adherence.
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Mon, Wed, Sat
New York DOH Approval Status
Plain Red, Lavender (K2 or K3EDTA) or Pink (K2EDTA).
Separate from cells ASAP or within two hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Refrigerated. Also acceptable: Room temperature or frozen.
Gel separator tubes. Hemolyzed specimens.
Ambient: 3 days; Refrigerated: 2 weeks; Frozen: 2 months (Avoid repeated freeze thaw cycles)
Clobazam is a benzodiazepine drug indicated for adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients 2 years and older. The therapeutic range is based on serum, pre-dose (trough) draw collection at steady-state concentration. The pharmacokinetics of clobazam are influenced by drug-drug interactions and by poor CYP2C19 metabolism. Adverse effects may include constipation, somnolence, sedation, and skin rash. The concomitant use of clobazam with other central nervous system (CNS) depressants may increase the risk of somnolence and sedation.
|Clobazam||Toxic: Greater than 500 ng/mL|
|N-Desmethylclobazam||Toxic: Greater than 5000 ng/mL|
Laboratory Developed Test (LDT)
80339 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|